EUSA Pharma hopes IL-6 drug will succeed in COVID-19 where rivals failedUK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 Share XEUSA Pharma hopes IL-6 drug will succeed in COVID-19 where rivals failedhttps://pharmaphorum.com/news/eusa-pharma-hopes-il-6-drug-will-work-in-covid-19-where-class-rivals-failed/
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavirGilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug Share XData sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavirhttps://pharmaphorum.com/news/data-sets-up-2021-filings-for-gileads-twice-a-year-hiv-drug-lenacapavir/
Adult data back Merck & Co’s challenger to Pfizer’s blockbuster Prevnar 13Merck & Co has built more momentum behind its attempt to depose Pfizer’s blockbuster pneumococcal conjugate vaccine Prevnar Share XAdult data back Merck & Co’s challenger to Pfizer’s blockbuster Prevnar 13https://pharmaphorum.com/news/adult-data-back-mercks-challenger-to-pfizers-blockbuster-prevnar-13/
Scynexis bids to end novel antifungal drought, filing ibrexafungerp in USScynexis has filed for FDA approval of its novel drug ibrexafungerp which – if approved – would be Share XScynexis bids to end novel antifungal drought, filing ibrexafungerp in UShttps://pharmaphorum.com/news/scynexis-bids-to-end-novel-antifungal-drought/
COVID-19 vaccine could be ready in time for US electionsHealth officials in the US have been told to prepare for a COVID-19 vaccine to be ready by Share XCOVID-19 vaccine could be ready in time for US electionshttps://pharmaphorum.com/news/covid-19-vaccine-could-be-ready-in-time-for-us-elections/
Ionis deal delivers for GSK as HBV drug hits the mark in phase 2An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a Share XIonis deal delivers for GSK as HBV drug hits the mark in phase 2https://pharmaphorum.com/news/ionis-deal-delivers-for-gsk-as-hbv-drug-hits-the-mark-in-phase-2/
Novo-backed $61m fundraising helps F2G prep for antifungal launchAnglo-Austrian biotech F2G has raised $60.8 million in venture financing to help it bring a drug for life-threatening Share XNovo-backed $61m fundraising helps F2G prep for antifungal launchhttps://pharmaphorum.com/news/novo-backed-61m-fundraising-helps-f2g-prep-for-antifungal-launch/
UK firms plan early-warning detector for COVID-19 in wastewaterSewage monitoring is being trialled as a way to spot new outbreaks of coronavirus, and three UK companies Share XUK firms plan early-warning detector for COVID-19 in wastewaterhttps://pharmaphorum.com/news/uk-firms-plan-early-warning-detector-for-covid-19-in-wastewater/
Gilead starts trials of inhaled remdesivir for earlier-stage COVID-19The first healthy volunteers have started to receive doses of Gilead’s inhaled formulation of remdesivir, which it hopes Share XGilead starts trials of inhaled remdesivir for earlier-stage COVID-19https://pharmaphorum.com/news/gilead-starts-trials-of-inhaled-remdesivir-for-earlier-stage-covid-19/
